Τίτλος:
Going the distance: Are we losing patients along the multiple myeloma treatment pathway?
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Despite data suggesting that individuals with multiple myeloma can benefit from receiving several lines of therapy, and guidelines recommending treatment after relapse, a recent European patient chart review found that only 61% of patients receive second-line treatment. The review found that factors such as old age and previous adverse events lead to physicians deciding not to treat after relapse. However, given the large number of regimens available, treatment can be tailored to individual patients’ needs and supportive care measures can help with the management of adverse effects. If approved therapies are not suitable for a patient, guidelines recommend registration in a clinical trial, yet only 7% of patients in the review were participating in such studies. A need for better education on the range of treatments available and their risk–benefit profiles is suggested. Access to new drugs should be examined to maximise the number of patients benefitting from them. © 2018 Elsevier B.V.
Συγγραφείς:
Terpos, E.
Suzan, F.
Goldschmidt, H.
Περιοδικό:
Critical Reviews in Oncology/Hematology
Εκδότης:
Elsevier Ireland Ltd
Λέξεις-κλειδιά:
bortezomib; carfilzomib; daratumumab; elotuzumab; ixazomib; lenalidomide; panobinostat; thalidomide; antineoplastic agent, cancer recurrence; clinical observation; clinical practice; comorbidity; cross-sectional study; European; human; medical record review; multiple myeloma; patient education; phase 3 clinical trial; practice guideline; progression free survival; retrospective study; Review; risk benefit analysis; chronic disease; clinical pathway; health care delivery; health personnel attitude; multiple myeloma; organization and management; patient abandonment; physician; standards; statistics and numerical data; treatment refusal; tumor recurrence, Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; Chronic Disease; Critical Pathways; Health Services Accessibility; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Physicians; Practice Patterns, Physicians'; Refusal to Treat; Treatment Refusal
DOI:
10.1016/j.critrevonc.2018.03.021
